A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”
But Will US Accept Initial Dataset?
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
